Viral hepatitis: Milestones, unresolved issues, and future goals

doi:10.3748/wjg.v27.i28.4603

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13435)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

943

WORD

239

HTML

9187

Figures (1-3)

1296

Tables (1-2)

261

Sum=11926

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

491

Download

1018

Sum=1509

Jul 28, 2021 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jul 28, 2021; 27(28): 4603-4638
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4603

Open in New Tab Full Size Figure Download Figure

Figure 1 Sustained virological response rate of hepatitis C virus antiviral treatment, from interferon to direct-acting antiviral agents’ regimens. SVR12: Sustained virologic response 12 wk post-treatment; IFN: Interferon; RBV: Ribavirin; peg-IFN: Pegylated interferon; PI: Protease inhibitor; SMV: Simeprevir; SOF: Sofosbuvir; LED: Ledipasvir; GLE: Glecaprevir; PIB: Pibrentasvir; VEL: Velpatasvir.

Open in New Tab Full Size Figure Download Figure

Figure 2 Indications for anti-hepatitis B virus therapy according to international guidelines. HBV: Hepatitis B virus; HCV: Hepatitis C virus; HDV: Hepatitis D virus; HCC: Hepatocellular carcinoma; HBeAg: Hepatitis B E antigen; HBsAg: Hepatitis B surface antigen; CHB: Chronic hepatitis B; ALT: Alanine aminotransferase; ULN: Upper limits of normal; DAA: Direct-acting antiviral agents.

Open in New Tab Full Size Figure Download Figure

Figure 3 Classification, hosts, and ways of transmission of the hepatitis E virus. HEV: Hepatitis E virus.

Citation: Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638
URL: https://www.wjgnet.com/1007-9327/full/v27/i28/4603.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i28.4603